Audio-Digest Foundation: family-practice

Main Written Summaries Listing | Family-practice: 2008 Listings
Audio-Digest FoundationFamily Practice


Volume 56, Issue 28
July 28, 2008

The following is an abstracted summary, not a verbatim transcript, of the lectures/discussions on this audio program. If, after reviewing this written summary, you would like to hear the contents and/or earn CME/CE credit:

View Main Program Listing

Visit Audio-Digest Home Page

Family Practice Program InfoAccreditation InfoCultural & Linguistic Competency Resources


processes); brain injury and neurologic disorders—injury to medial frontal area may cause apathetic syndromes; strokes that affect frontal area often associated with depression; other patterns of behavior (eg, disinhibition, mania) associated with other injuries and disorders; early life experiences—traumatic experiences at young age may lead to neural changes and increased susceptibility to psychiatric disorders; interaction—relationships among internal and external factors and mood are complex; categorizing depression as “reactive” or “endogenous” too simplistic
Active listening: “listen with two ears”; diagnostic—recognize signs and symptoms that indicate treatable syndrome (eg, major depressive disorder); use diagnosis to guide management; empathetic—piece together narrative of life events and responses; identify underlying vulnerabilities and contributory circumstances; seek to understand patient as individual and reasons for current crisis
Diagnosis: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) lists signs and symptoms of depression (eg, sleep disturbance, loss of interest in activities, inappropriate guilt, loss of energy, mood changes, reduced concentration, changes in appetite, depressed psychomotor response, suicidality); depressive episode defined as 5 symptoms for 2 wk
Distinctive symptoms of major depression: melancholy—intractable and debilitating; diminished vital sense—decreased mental and physical potency; reduced zest for life and capacity for pleasure; diminished self-regard—decreased confidence and self-efficacy; increased “blameworthiness” and sensitivity to and preoccupation with errors; diurnal pattern of distress—symptoms worse in morning and improve throughout day; note, diurnal pattern of physical symptoms (eg, nausea and stomachache) also may indicate depression
Alcohol abuse or intoxication: always ask about alcohol use; patients may not volunteer information; simulates depression—contributes to mood instability; causes interval insomnia and disturbed continuity of sleep; affects appetite and mood; complicates depression—lowers threshold for self harm (intoxication increases likelihood of acting on suicidal thoughts); age of onset—alcohol abuse may begin late in life, often in association with stress specific to life phase (eg, ailing spouse)
Wish to hasten death: studies looking at terminally ill patients have found that patients wishing to hasten death also have symptoms of major depression; psychologic distress often more important factor than physical pain among people who ask for physician-assisted suicide (data from Oregon); anecdotal evidence suggests that terminally ill patients with concomitant major depression no longer wish to hasten death once depression treated
Assessment of suicide risk: among older individuals, depression most common reason for suicide; expressed intentions—important to ask about suicidal ideation or plans, but many suicidal patients deny intentions; mental status— high-risk findings include psychic pain, self-loathing, and hopelessness (“lethal triad”); other red flags include perturbation, delusions of guilt, hallucinations advising suicide, and passive wishes for death; history—patients with past attempts at suicide at highest risk; other red flags include history of acute demoralizing crisis and concurrent substance abuse
Expectant trust: conceptualized by Jerome Frank; patient perception that clinician cares, is competent and optimistic about outcome, and will not abandon patient; attitude inspires hope (important for treatment of depression and prevention of suicide)
Formulation of narrative: assess vulnerabilities (eg, personality traits, psychosocial circumstances, substance abuse), current stressors and life circumstances (eg, conjugal bereavement), and how these interact to create current crisis (eg, loneliness, suicidality); approach to treatment—leverage strengths to compensate for vulnerabilities and resolve crisis
Response to medical therapy: depression generally does not remit with first intervention; Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial looked at response to pharmacotherapy among 4000 outpatients (few exclusions; population representative of most practice settings); level 1—depression remitted in 30% of patients after first intervention (substantial trial with citalopram); level 2—for remaining patients, augmenting treatment with bupropion (eg, Wellbutrin) or buspirone (Buspar) resulted in remission in 30% of patients in each group; switching to sertraline (Zoloft), venlafaxine (Effexor), or bupropion resulted in remission in 18%, 25%, and 21%, respectively; level 3— augmenting treatment with lithium or triiodothyronine resulted in remission in 16% and 25% of patients in each group; switching to mirtazapine (Remeron) or nortriptyline resulted in remission in 12% and 20%, respectively; level 4— switching to monoamine oxidase inhibitor (MAOI) or combination of venlafaxine plus mirtazapine resulted in remission in 7% and 14%, respectively; overall results—remission achieved in 70% of patients; numerous extended trials often necessary
Maintenance pharmacotherapy: important, especially for older patients who respond to pharmacotherapy; randomized placebo-controlled study compared maintenance therapy to paroxetine (eg, Paxil) and psychotherapy; depression recurred less frequently (35%-37%) among patients treated with paroxetine (with or without psychotherapy), compared to those treated with psychotherapy or placebo alone (68% and 58%, respectively)
Electroconvulsive therapy (ECT): appropriate for patients unresponsive to pharmacotherapy and for those in imminent danger; single most effective treatment for acute episodes of major depression; usually well tolerated, even by very old patients; adverse effects—cardiovascular effects (eg, arrhythmias) relatively uncommon, and usually benign and manageable; cognitive effects (eg, memory loss) highly variable and not dependent on age; risk for adverse cognitive effects increases with number and frequency of treatments and bilateral (vs unilateral) electrostimulation; usually time-limited; effect—ECT interrupts depressive episode, but does not prevent relapse (therefore, additional treatment necessary); maintenance ECT—weekly, biweekly, or monthly sessions may be effective; interval shortened or extended as necessary to prevent recurrence of serious depression
Persistence and vigilance: critical; continuity of care and ongoing assessment of, eg, therapeutic response, adverse effects, emergent problems, necessary; important for clinician to remain supportive and optimistic
Questions and answers: treatment history—ask about efficacy and tolerability of previously used antidepressants; choice and dosing of antidepressants—speaker begins with low-dose selective serotonin reuptake inhibitor (SSRI; eg, citalopram 5 mg), then increases dose every week, as tolerated; if additional therapy needed once adequate dose reached, speaker adds buspirone (based on results from STAR*D trial)
DELIRIUM AND ALZHEIMER’S DISEASE —Joel D. Posner, MD, Professor of Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY
Aging population: individuals \>65 yr of age represent 17% of population of United States; aging baby boomers (cohort of 80 million people) beginning to face age-related health issues
Delirium and dementia: often overlooked or minimized; delirium (acute; medical emergency) may occur in patients with baseline dementia, but may go unrecognized and untreated
Assessing mental status: baseline assessment required in order to recognize changes in mental status; Mini-Mental State Examination (MMSE) recommended annually (requires <10 min; may be performed by auxiliary staff); change in score indicates change in mental status; components of MMSE—orientation; registration; attention; calculations; recall; language; assessment of orientation normally made by asking about state and country; speaker prefers to ask questions about time, place (ie, setting), and person

Delirium
General: acute change in mental status; potentially life-threatening medical emergency; waxing and waning levels of consciousness distinguishes delirium from dementia (chronic; relatively stable); agitation and visual hallucinations also common
Reversible causes: mnemonic spells DEMENTIA
Drugs: prescription and over-the-counter (OTC) medications; sleep medications, psychiatric medications, anticholinergic agents (including OTC antihistamines), and others may cause acute confusion
Endocrine abnormalities: eg, hyperthyroidism and hypothyroidism associated with atypical signs in older adults
Metabolic causes: hypoxia (eg, during sleep, exercise, or normal activities); hypoglycemia; electrolyte imbalance (eg, diuretic use may result in hyponatremia, causing acute confusion and risk for death); impaired function of liver or kidneys
Ears, eyes, and emotions: impaired hearing or vision may increase confusion and lead to odd behaviors; depression may present as acute confusional state
Nutrition and normal-pressure hydrocephalus: deficiencies of vitamin B12 , folate, or thiamine may accompany alcohol abuse, and may represent medical emergency (parenteral supplementation required); identification of normal-pressure hydrocephalus has treatment implications for patients <75 yr of age
Takes up space in brain: eg, tumors, trauma, subdural hematoma
Infections: atypical presentations common among older adults
Arteries: anything that prevents oxygenated blood from reaching brain (eg, heart failure, cardiac arrhythmias); acute confusional state (without chest pain or shortness of breath) is presenting symptom of myocardial infarction in 25% of adults \>85 yr of age
Work-up: history and physical examination; MMSE or other assessment of mental status; laboratory tests—complete blood cell (CBC) count (detects severe anemia and evidence of infection); sedimentation rate (high rate may signal arteritis, especially when accompanied by acute confusion); thyroid function tests; electrolyte levels; renal function tests; blood glucose levels; vitamin B12 and folate levels (methylmalonic acid test for B12 ; homocysteine levels better indicator of folate status than serum level of folic acid; supplement empirically); other tests—electrocardiography; oximetry; chest x- ray; computed tomography (CT; identifies normal-pressure hydrocephalus); magnetic resonance imaging (MRI; visualizes old aneurysms not visible on CT); magnetic resonance arteriography (MRA; visualizes blood vessels)

Alzheimer’s Disease (AD)
Types of dementia: purely vascular (5%); vascular dementia plus AD (10%); AD alone (65%); AD plus Lewy body disease (5%; progresses relatively rapidly; marked by strange behavior)
Pathology: characterized by neurofibrillary tangles and amyloid plaques in brain; pathophysiology and treatment implications—amyloid plaques impair function of nerves, disturbing memory cognition and behavior; prevention of plaques may prevent progression of AD; current treatment based on cholinergic hypothesis (ie, low levels of acetylcholine results in diminished transmission of impulses across synapses)
Research: valsartan—prevents amyloid clumping in humans and blocks memory loss in rat models of AD; low-density lipoprotein receptor-related protein (LRP)—levels and potency reduced among patients with AD; exogenous LRP-4 clears amyloid- β in brains of humans and rats and prevents memory loss in rats; potential implications for treatment
Early signs of AD: 3 yr before diagnosis, 40% of patients experience social withdrawal; depression affects 60% of patients 2 yr before diagnosis; 20% of patients become paranoid 1.5 yr before diagnosis; importance of recognizing early signs—management implications; patient and families can make proper arrangements
Clinical ABCs: activities of daily living (ADLs); behavior; cognition; mild AD—problems with executing routine tasks; changes in behavior and personality; moderate degree of confusion and memory loss; moderate AD—patients require assistance with ADLs (eg, feeding, bathing, dressing) and may exhibit paranoia, insomnia, and anxiety; memory loss becomes more chronic; severe AD—characterized by speech loss, inability to recognize friends and family, and general loss of function
Treatment: current approach based on cholinergic mechanism; acetylcholinesterase breaks down acetylcholine; cholinesterase inhibitors inhibit action of acetylcholinesterase and increase levels of acetylcholine; adverse effects— gastrointestinal upset (sometimes severe); slow titration of medication necessary; donepezil—begin with 5 mg at bedtime; increase to 10 mg after 4 to 6 wk; rivastigmine—must be taken with food; begin with 1.5 mg bid; increase to 3 mg bid (minimum effective dose in most patients) after 4 wk; increase to 4.5 mg, then 6.0 mg (titrating every 4 wk), if tolerated; galantamine—must be taken with food; begin with 4 mg bid; increase by 4 mg every 4 wk, with maximum dose of 12 mg bid (use minimum effective dose); memantine—use in combination with other medications; after dose of primary medication stabilized, begin with 5 mg/day; increase to 5 mg bid, then add 5 mg/day in divided doses until maximum dose (10 mg, bid) reached
Efficacy: modest; patients taking donepezil or rivastigmine have improved cognitive performance, compared to those taking placebo; early initiation of treatment may improve results; little evidence of effect on ADLs or behavior

Suggested Reading

APA Work Group on Alzheimer’s Disease and other Dementias: American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry 164(12 Suppl):5, 2007; Caplan JP: Too much too soon? Refeeding syndrome as an iatrogenic cause of delirium. Psychosomatics 49:249, 2008; Feart C et al: Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr 87:1156, 2008; Feldman HH et al: Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 178:825, 2008; Grossman M et al: Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology 70:2036, 2008; Heo M et al: Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050. Int J Geriatr Psychiatry May 23, 2008 [Epub ahead of print]; Hoogendijk WJ et al: Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 65:508, 2008; Nelson JC et al: Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry May 12, 2008 [Epub ahead of print]; Niu K et al: Home blood pressure is associated with depressive symptoms in an elderly population aged 70 years and over: a population-based, cross-sectional analysis. Hypertens Res 31:409, 2008; Richard KL et al: Toll-like receptor 2 acts as natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J Neurosci 70:2036, 2008; Sun X et al: amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65:542, 2008; Voelker R: Guideline: dementia drugs’ benefits uncertain. JAMA 299:1763, 2008; Wei LA et al: The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc 56:823, 2008; Wiesenfeld L: Delirium: the ADVISE approach and tips from the frontlines. Geriatrics 63:28, 2008.

Reproduction of this summary in whole or in part in any form or medium without express written permission is prohibited.

If, after reviewing this written summary, you would like to hear the contents and/or earn CME/CE credit:

View Main Program Listing

Visit Audio-Digest Home Page